Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the combined occurrence of parathyroid, pancreatic islet and anterior pituitary tumours. To facilitate a screening programme for MEN1, we investigated 709 people (364 males and 345 females, age range 1-84 years) from 62 MEN1 families, and 36 nonfamilial MEN1 patients. Of those investigated, 220 (95 males and 125 females, age range 8-79 years) suffered from MEN1. Parathyroid, pancreatic and pituitary tumours occurred in 95%, 4 1 % and 30% of the patients, respectively. Parathyroid tumours were the first manifestation of MEN1 in 87% of patients, and amongst the pituitary and pancreatic tumours, somatotrophinomas and gastrinomas were more common in patients above the age of 40 years, whilst insulinomas occurred more frequently in patients below the age of 40 years. Biochemical screening indicated that the penetrance of MEN1 by the ages of 20, 35 and 50 years was 43%, 85% and 94%, respectively, and that the development of MEN1 was confined to first-degree relatives in 9 1 % of patients and to second-degree relatives in 9% of patients. These findings have helped to define a proposed screening programme for MEN1.
Introduction
Multiple endocrine neoplasia type 1 (MEN!) 1 is an autosomal dominant disorder characterized by the combined occurrence of tumours of the parathyroid glands, the pancreatic islet cells and the anterior pituitary. 1 " 5 Parathyroid tumours are the most common manifestation of the disorder 6 " 10 but patients may also suffer from pancreatic tumours which secrete gastrin, insulin, pancreatic polypeptide (PP), or glucagon, and anterior pituitary tumours which usually secrete prolactin, growth hormone (GH) or adrenocorticotrophin (ACTH). 4 " 10 Adrenal cortical tumours, 11 carcinoid tumours, 12 lipomatous tumours 7 and the McCune-Albright syndrome 13 have also been observed in association with MEN1. The disease may arise in families, and an autosomal dominant inheritance has been established. 2 ' 3 Children of an affected individual are thus at a 50% risk of inheriting the mutant gene and of potentially developing these endocrine tumours. Earlier detection of these tumours by screening may help to reduce the morbidity and mortality in this high-risk population. However, screening for MEN1 is difficult as the combination of affected glands may differ in members of the same family. 1 In addition, the age-related penetrance (the proportion of gene carriers who have manifested symptoms or signs of the disease by a given age) has not been established. We used clinical and biochemical methods to investigate the members of 98 families with MEN1, aiming to characterize further its manifestations, to determine its age-related penetrance, and to define a suitable screening strategy.
Methods Patients
Ninety-eight unrelated MEN! patients were studied and their detailed family medical histories obtained.
Patients and their family members were assessed for present and past manifestations of MEN1: polyuria, polydipsia, constipation, malaise, bone pains or nephrolithiasis suggesting hypercalcaemia, indigestion, recurrent peptic ulceration, hypoglycaemia, neuroglycopenia or diarrhoea suggesting the presence of a pancreatic islet-cell tumour, amenorrhoea, galactorrhoea, impotence or weight changes suggesting the presence of a pituitary tumour and a detailed questionnaire (Appendix I) completed. The medical records of deceased family members and of the known affected individuals were also examined.
Biochemical measurements
Venous blood samples were obtained from patients and family members, and serum calcium, albumin, creatinine and alkaline phosphatase were determined using a multi-channel autoanalyser. 14 Serum calcium concentrations were corrected to an albumin of 41 g/l 14 (normal range 2.25-2.55 mmol/l). Serum prolactin was also determined in all individuals using the Serono immunoradiometric assay 15 (normal range < 5 0 0 mlU/l). Estimations of other anterior pituitary hormones, gastrointestinal hormones, serum insulin and glucose were made if indicated from the clinical history and examination.
Phenotype allocation
Individuals were taken to be affected if they had evidence of two or more MEN 1-associated tumours, or if they were the relative of an affected individual and had evidence of one MEN1 tumour as determined by the following characteristics: (i) persistent hypercalcaemia (corrected calcium >2.55 mmol/l); (ii) persistent hyperprolactinaemia (defined by a serum prolactin of > 8 0 0 mlU/l, so as to exclude stress-related hyperprolactinaemia) occurring in the absence of a known cause, such as pregnancy, hypothyroidism, or drugs, e.g. phenothiazines, together with other radiological or surgical evidence of a pituitary tumour; (iii) biochemical and/or radiological abnormalities demonstrating acromegaly or Cushing's disease (iv) biochemical and/or radiological abnormalities demonstrating a gastrinoma, insulinoma, PPoma, VIPoma or glucagonoma.
Kinship coefficient
Individuals were designated a kinship coefficient (KC) as an index of their proximity to affected members. 7 KCs were assigned prior to biochemical screening, and known affected individuals were designated a KC of 1.0; first-degree unaffected relatives, i.e. siblings and children of an affected individual, were designated a KC of 0.5; and seconddegree unaffected relatives, i.e. grandchildren, nephews and nieces, were assigned a KC of 0.25. Spouses, who were also screened for MEN1 to ensure that they were unaffected and therefore not transmitting MEN1 to their children, were assigned a KC of 0.
Data analysis
The clinical and biochemical information for each individual was entered into a database using the DATAEASE computer program on an IBM PC, and statistical analysis was performed with the MINITAB package. The incidence of insulinomas by age and its correlation with the number of mutations required for its development was assessed by plotting the proportion of patients not yet diagnosed (S) at a given age against the age (t), as previously described for the development of retinoblastoma and Knudson's two-hit hypothesis. 16 Thus, the incidence by age of tumours that develop after a single mutation, e.g. familial forms, would conform to a first-order equation log 10 S = a -kt, whereas that of tumours developing as a result of two mutations, e.g. the sporadic forms, would conform to a second-order equation log 10 S = a -kt 2 . The ages at which insulinomas developed in familial MEN1 patients and sporadic non-MENI patients were determined from our study and a previously reported study, 17 respectively, and used for these calculations. 
Results

Details of patients and families
Analysis of tumour types
The 220 affected individuals had a total of 384 tumours (Appendix II); 120 of these patients had two or more tumours and the remaining 100 patients had one tumour. The distribution of the tumours is shown in Figure 2 . Hypercalcaemia was found in 208 (94.5%) patients; the diagnosis of primary hyperparathyroidism had been confirmed in 87% of these patients by either parathyroidectomy (71 %) or persistently raised serum PTH concentrations (16% (Figures 1 and 3 ) and which occurred as the sole endocrinopathy in 42.3% of MEN1 patients. Pancreatic tumours occurred in 40% of patients, with gastrinomas being the most common (63%) and with insulinomas being the next most common (27%) tumours; three of these tumours secreted both gastrin and insulin, and two of the gastrinomas also secreted glucagon. The gastrinomas were confirmed surgically or radiologically in 80% of patients and the insulinomas were confirmed surgically in 96% of patients. Pituitary tumours occurred in 30% of patients. Over three-fifths were prolactinomas and the majority of the remainder were somatotrophinomas. Ninety-six percent of the prolactinomas and 93% of the somatotrophinomas were confirmed by surgery or radiology. Additional endocrine tumours were found in 21 individuals: carcinoid tumours in eight patients (4%), adrenal 16/9211.1 • -S17
• -S8
• cortical tumours in 12 patients (5%), lipomata in two patients (1%), a phaeochromocytoma in one patient, and a testicular teratoma and a malignant melanoma in one patient. Of these 21 patients, one patient had both a non-functioning adrenal tumour and a phaeochromocytoma, one patient had both an adrenal tumour and a carcinoid tumour, and the patient with a testicular teratoma and a malignant melanoma also had a carcinoid tumour.
The combinations of these MEN1 tumours differed in members of the same family, and this variable expression of MEN1 is illustrated by family 13/89 ( Figure 1 ). In this family the father (generation II) suffered from parathyroid tumours, an insulinoma and a prolactinoma. All of his six affected children (generation III) suffered from parathyroid tumours but three daughters and one son had a prolactinoma whilst another son had a somatotrophinoma. In addition, one of his daughters suffered from an insulinoma whereas a son suffered from a gastrinoma. The interval between the appearance of each tumour in a patient also varied and ranged from 6 to 24 years in the 15 MEN1 patients in whom the order of tumour development could be unequivocally established (Figure 3 ).
Age-related penetrance and a mutational model
The ages at which the first manifestation of an MEN1 tumour occurred could be established in 219/220 100-, MEN1 patients and ranged from 8 to 79 years. Sixtysix of these 219 patients were asymptomatic and had been detected by biochemical screening; the remaining 153 patients had presented with symptoms. The cumulative percentages of patients who had developed MEN1 in the symptomatic group at the ages of 20, 35 and 50 years were 18%, 52% and 78%, respectively, whereas in the biochemicallyscreened asymptomatic group, these respective cumulative percentages were increased to 43%, 85% and 94% (Figure 4a ). Thus biochemical screening detected an earlier onset (p<0.001) of MEN1 in all age groups. The age-related penetrance (the proportion of gene carriers who have manifested symptoms or signs of the disease by a given age) of MEN1 was determined , and S7 (Appendix II). All four males had primary hyperparathyroidism, one also had an insulinoma and another also suffered from a corticotrophinoma; the one female, who suffered from an insulinoma and a non-functioning pituitary tumour, did not have hypercalcaemia. However, the expected 50% ratio for an autosomal dominant disorder was attained by 21 years and maintained until 40 years of age, after which it decreased to 42%. This decrease was attributed to the higher mortality associated with the gastrinomas and somatotrophinomas ( Figure 5 ). These results indicate that MEN1 has a high penetrance by the age of 21 years.
and the results from 288 offspring (129 affected, 159 unaffected) of 101 affected parents are shown in Figure 4b . The decline observed above the age of 40 years in the ratio of affected individuals to the total number of individuals could result either from an increased number of unaffected individuals or a decreased number of affected individuals. The former possibility is clearly implausible, and the latter possibility, which may be due to a greater death rate in MEN1 patients above the age of 40 years was indirectly assessed by investigating the age distribution ( Figure 5 ) of the 384 tumours (Figure 1 ) in the affected individuals. The results revealed that above the age of 40 years, there was a higher occurrence of gastrinomas and somatotrophinomas, which would be associated with a higher mortality. Such differences were not observed for the occurrence of parathyroid tumours and prolactinomas in the two age groups ( Figure 5 ) but insulinomas were found to occur more frequently in the younger age group, and this may partly contribute to the decline in the ratio of affected individuals to the total between the ages of 13 and 17 years (Figure 4b ).
This significantly (p<0.01) higher occurrence of insulinomas in the younger age group ( Figure 5 ) may also be due to their neuroglycopenic presentation, which would result in their earlier detection when compared with other MEN1 tumours. A further analysis of the ages at which the 26 MEN1 insulinomas occurred and their comparison to the previously reported ages at which 57 non-MEN1 insulinomas 17 occurred helped to estimate the number of mutations which were likely to be required for their development. The mean age ( + SD) at which insulinomas were detected in the MEN1 patients (28.86±19.09) was significantly (p<0.04) lower than that in the non-MEN1 patients (45.98 + 16.96). An analysis of the age of incidence for MEN1 insulinomas and for non-MEN1 insulinomas gave similar results to those reported for bilateral and unilateral retinoblastomas, 16 16 The age is plotted on the x axis and the corresponding log 10 S, which is the proportion of cases not yet diagnosed, is plotted on the y axis. The incidence by age of the familial MEN1 insulinomas (n = 26) is best described by the first-order equation y=0.024x + 2.169 (r = 0.994), whereas that of the sporadic non-MENI insulinomas is best described by the second-order equation y= -0.0004653X 2 rather than a first-order equation (p<0.001). These results indicate that a single mutation is likely to be associated with the development of MEN1 insulinomas whereas two mutations are likely to be involved in the development of sporadic non-MEN1 insulinomas. ively ( Figure 6 ). Thus, the relationship between log 10 S (the proportion of cases not yet diagnosed) and t (the age) was best described by a first-order equation for the MEN1 insulinomas and by a second-order equation for the non-MEN1 insulinomas. This situation is analogous to that for the retinoblastoma model in which two recessive mutations of a tumour suppressor gene are involved in oncogenesis; thus, MEN1 insulinomas require a single mutation, whereas non-MEN1 insulinomas require additional mutations.
Hypercalcaemia and coefficient of kinship
Parathyroid tumours are the most common and usually the first manifestation of MEN1 (Figures 2  and 3 ) and the detection of hypercalcaemia in members of MEN1 families represents a useful biochemical screening investigation. In order to assess which relatives of an MEN1 patient should be screened, we analysed the pre-treatment corrected serum calcium concentrations from 602 individuals according to their coefficient of kinship, KC (Figure 7) . The corrected serum calcium concentrations for those individuals without previous parathyroid surgery (mean + SD) in the KC 1.0 group^ are not yet widely available, will help to identify those individuals with an affected haplotype 27 who have the greater likelihood of developing MEN1 tumours. Individuals identified either by KC or molecular genetic analysis as at higher risk should be entered into the screening programme as outlined.
(2.88 + 0.40, n = 65), was significantly (p<0.001) higher than in the KC 0.5 (2.42 + 0.19, n = 202), KC 0.25 (2.32 + 0.13, n = 150) and KC 0.125 (2.30 + 0.06, n = 24) groups. In addition, hypercalcaemia was observed in 91%, 19%, and 4% of the individuals in KC 1.0, 0.5 and 0.25 groups, respectively, but in 0% of the KC 0.125 group. These results indicate that hypercalcaemia is a useful investigation for the biochemical screening of MEN1 which has a high penetrance, and that such screening could be restricted to the first (KC = 0.5) and second (KC = 0.25) degree relatives of affected individuals.
Discussion
Our extensive study of 220 MEN1 patients has helped to define the manifestations and age-related penetrance of this autosomal dominant disorder. Parathyroid tumours were the first and most common of the lesions to develop, occurring in 87% and 94% of patients, respectively (Figures 2  and 3 ). In addition, pancreatic islet-cell tumours and anterior pituitary adenomas occurred in 40% and 30% of patients, respectively, with gastrinomas and prolactinomas representing the majority of tumours in each of these respective categories. The occurrence of carcinoid tumours, adrenal cortical tumours and lipomata was 4%, 5%, and 1 % in the patients, respectively. Our results, which represent the largest study of MEN1 patients and are comparable to those of previous reports, 1 " 4 ' **~9 > 18~20 also demonstrated the highly variable expression of MEN1. Thus, although the majority of patients had parathyroid tumours, the types of subsequent tumours originating from the pancreatic islets and the anterior pituitary showed considerable interand intra-familial variation (Figure 1 ). In addition, the time interval between the development of the first and subsequent tumours in a patient also varied considerably from 6 to 24 years ( Figure 3) . Our results are the first to demonstrate that gastrinomas and somatotrophinomas occur more frequently in MEN! patients who are above the age of 40 years, that insulinomas occur more frequently in MEN1 patients who are below the age of 40 years ( Figure 5 ), and that the genetic aetiology of MEN1 insulinomas ( Figure 6 ) is consistent with Knudson's two-hit hypothesis. 16 ' 21 " 23 In addition, our defining of the age-related onset for MEN1 tumours, which were confined to the first (KC = 0.5) and second (KC = 0.25) degree relatives (Figure 7) , helped in the estimation of residual risks (i.e. 100% -[agerelated onset % ] , Figure 4a ), for these individuals. Thus, the residual risks for developing MEN1 tumours in such unaffected relatives who are biochemically normal are estimated to be 57%, 15% and 6% at the ages of 20, 35, and 50 years, respectively. These results have facilitated the development of a proposed screening programme to help in the management of members from MEN1 families (Figure 8 ). Screening should be initiated before 8 years of age, as affected children (III.4 from family 7/87 and IV.7 from family 18/89, Appendix II) have been observed by this age. Biochemical screening should be undertaken in those with a KC^0. 25 . In addition, the use of molecular genetic markers that are close to the MEN1 gene 24 F  F  F   38  28  19  14  8  29  29  22  25  67  29  18  17  42  52  55  35  29  26  39  24  35  32  17  51  75  20  30  45  25  42  18  55  21  32  25  22  20  18  52  33  27  37  32  33  25  15  20  17  12  60  53  53  47  54  15 Age of  detection   56  51  40  50  26  60  51  20  27  44  12  57  35  19  20  34  47  59  37  27  79  52  10  48  50  17  57  18  47  42  42  44  30  46  20  37  31  47  19  63  32  28  43  12 
